Phase III study on efficacy of taxanes plus bevacizumab with or without capecitabine as first-line chemotherapy in metastatic breast cancer

Breast Cancer Research and Treatment

Volumn 149, Issue 1, 2015, Pages 141-149

  Lück, Hans Joachim ^a   Lübbe, Kristina ^b   Reinisch, Mattea ^c   Maass, Nicolai ^d   Feisel Schwickardi, Gabriele ^e   Tomé, Oliver ^f   Janni, Wolfgang ^g   Aydogdu, Mustafa ^h   Neunhöffer, Tanja ⁱ   Ober, Angelika ^j   Aktas, Bahriye ^k   Park Simon, Tjoung Won ^l   Schumacher, Claudia ^m   Höffkes, Heinz Gert ⁿ   Illmer, Thomas ^o   Wagner, Harald ^p   Mehta, Keyur ^c   von Minckwitz, Gunter ^c   Nekljudova, Valentina ^c   Loibl, Sibylle ^c  

^a Gynecologic Oncology Practice Hannover   (Germany)

^b Henriettenstiftung   (Germany)

^c GERMAN BREAST GROUP   (Germany)

^d RWTH AACHEN UNIVERSITY   (Germany)

^e KLINIKUM KASSEL   (Germany)

^f St Vincentius Clinic Karlsruhe   (Germany)

^g UNIVERSITY HOSPITAL ULM   (Germany)

^h KLINIKUM BREMEN MITTE   (Germany)

ⁱ DR HORST SCHMIDT KLINIKEN   (Germany)

^j St Vincenz Hospital Limburg   (Germany)

^k UNIVERSITY HOSPITAL ESSEN   (Germany)

^l HANNOVER MEDICAL SCHOOL   (Germany)

^m St Elisabeth Hospital   (Germany)

ⁿ KLINIKUM FULDA   (Germany)

^o Practice for Internal Medicine and Hematology Dresden   (Germany)

^p Oncological Clinic Drs med Wilke Wagner   (Germany)

more..

Author keywords

Bevacizumab; Capecitabine; Metastatic breast cancer; Progression free survival; Response; Taxane

Indexed keywords

BEVACIZUMAB; CAPECITABINE; DOCETAXEL; PACLITAXEL; ANTINEOPLASTIC AGENT; DEOXYCYTIDINE; FLUOROURACIL; MONOCLONAL ANTIBODY; TAXOID;

ADULT; AGED; ALLERGIC REACTION; ANEMIA; ARTERIAL THROMBOEMBOLISM; ARTICLE; BLEEDING; BREAST METASTASIS; CANCER COMBINATION CHEMOTHERAPY; CONGESTIVE HEART FAILURE; CONTROLLED STUDY; DIARRHEA; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG FATALITY; DRUG RESPONSE; DRUG SAFETY; DRUG SUBSTITUTION; DRUG WITHDRAWAL; EMBOLISM; ESOPHAGITIS; FATIGUE; FISTULA; HAND FOOT SYNDROME; HEART LEFT VENTRICLE FAILURE; HEMATOLOGIC DISEASE; HUMAN; HYPERTENSION; INFECTION; LEUKOPENIA; MAJOR CLINICAL STUDY; MEDICATION COMPLIANCE; MUCOSA INFLAMMATION; MULTIPLE CYCLE TREATMENT; NEPHRITIS; NEUTROPENIA; OVERALL SURVIVAL; PATIENT COMPLIANCE; PERFORATION; PHASE 3 CLINICAL TRIAL; POSTERIOR REVERSIBLE ENCEPHALOPATHY SYNDROME; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROSPECTIVE STUDY; PROTEINURIA; RANDOMIZED CONTROLLED TRIAL; SENSORY NEUROPATHY; STOMATITIS; THROMBOSIS; TREATMENT DURATION; UNSPECIFIED SIDE EFFECT; ADVERSE DRUG REACTION; ANALOGS AND DERIVATIVES; BREAST NEOPLASMS; CLINICAL TRIAL; DISEASE FREE SURVIVAL; FEMALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; PATHOLOGY;

ADULT; AGED; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; DEOXYCYTIDINE; DISEASE-FREE SURVIVAL; DRUG-RELATED SIDE EFFECTS AND ADVERSE REACTIONS; FEMALE; FLUOROURACIL; HUMANS; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; TAXOIDS;

EID: 84925539015     PISSN: 01676806     EISSN: 15737217     Source Type: Journal    
DOI: 10.1007/s10549-014-3217-y     Document Type: Article

References (16)

1. Gennari A, Conte P, Rosso R, Orlandini C, Bruzzi P (2005) Survival of metastatic breast carcinoma patients over a 20-year period: a retrospective analysis based on individual patient data from six consecutive studies. Cancer 104:1742–1750
2. Giordano SH, Buzdar AU, Smith TL, Kau SW, Yang Y, Hortobagyi GN (2004) Is breast cancer survival improving? Cancer 100:44–52
3. Ufen MP, Köhne CH, Wischneswky M, Wolters R, Novopashenny I, Fischer J, Constantinidou M, Possinger K, Regierer AC (2014) Metastatic breast cancer: are we treating the same patients as in the past? Ann Oncol 25:95–100
4. Miller K, Wang M, Gralow J, Dickler M, Cobleigh M, Perez EA, Shenkier T, Cella D, Davidson NE (2007) Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer. N Engl J Med 357:2666–2676
5. Miles DW, Chan A, Dirix LY, Cortés J, Pivot X, Tomczak P, Delozier T, Sohn JH, Provencher L, Puglisi F, Harbeck N, Steger GG, Schneeweiss A, Wardley AM, Chlistalla A, Romieu G (2010) Phase III study of bevacizumab plus docetaxel compared with placebo plus docetaxel for the first-line treatment of human epidermal growth factor receptor 2-negative metastatic breast cancer. J Clin Oncol 28:3239–3247
6. Robert NJ, Diéras V, Glaspy J, Brufsky AM, Bondarenko I, Lipatov ON, Perez EA, Yardley DA, Chan SY, Zhou X, Phan SC, O’Shaughnessy J (2011) RIBBON-1: randomized, double-blind, placebo-controlled, phase III trial of chemotherapy with or without bevacizumab for first-line treatment of human epidermal growth factor receptor 2-negative, locally recurrent or metastatic breast cancer. J Clin Oncol 29:1252–1260
7. Brufsky AM, Hurvitz S, Perez E, Swamy R, Valero V, O’Neill V, Rugo HS (2011) RIBBON-2: a randomized, double blind, placebo-controlled, phase III trial evaluating the efficacy and safety of bevacizumab in combination with chemotherapy for second-line treatment of human epidermal growth factor receptor 2-negative metastatic breast cancer. J Clin Oncol 29:4286–4293
8. O’Shaughnessy J, Miles D, Vukelja S, Moiseyenko V, Ayoub JP, Cervantes G, Fumoleau P, Jones S, Lui WY, Mauriac L, Twelves C, Van Hazel G, Verma S, Leonard R (2002) Superior survival with capecitabine plus docetaxel combination therapy in anthracycline-pretreated patients with advanced breast cancer: phase III trial results. J Clin Oncol 20:2812–2823
9. Lück HJ, Du Bois A, Loibl S, Schrader I, Huober J, Heilmann V, Beckmann M, Stähler A, Jackisch C, Hubalek M, Richter B, Stickeler E, Eidtmann H, Thomssen C, Untch M, Wollschläger K, Schuster T, von Minckwitz G (2013) Capecitabine plus paclitaxel versus epirubicin plus paclitaxel as first-line treatment for metastatic breast cancer: efficacy and safety results of a randomized, phase III trial by the AGO Breast Cancer Study Group. Breast Cancer Res Treat 139:779–787
10. Parmar MK, Griffiths GO, Spiegelhalter DJ, Souhami RL, Altman DG, van der Scheuren E, CHART steering committee, (2001) Monitoring of large randomised clinical trials: a new approach with Bayesian methods. Lancet 358:375–381
11. Miles DW, Diéras V, Cortés J, Duenne AA, Yi J, O’Shaughnessy J (2013) First-line bevacizumab in combination with chemotherapy for HER2-negative metastatic breast cancer: pooled and subgroup analyses of data from 2447 patients. Ann Oncol 24:2773–2780
12. Gradishar WJ, Meza LA, Amin B, Samid D, Hill T, Chen YM, Lower EE, Marcom PK (2004) Capecitabine plus paclitaxel as front-line combination therapy for metastatic breast cancer: a multicenter phase II study. J Clin Oncol 22:2321–2327
13. European Medicines Agency (2010) European Medicines Agency completes its review of Avastin used in breast cancer (Press release 16/12/2010). http://www.ema.europa.eu/ema/index.jsp?curl=pages/news_and_events/news/2010/12/news_detail_001166.jsp&mid=WC0b01ac058004d5c1. Accessed 06 October 2014
14. Lang I, Brodowicz T, Ryvo L, Kahan Z, Greil R, Beslija S, Stemmer SM, Kaufman B, Zvirbule Z, Steger GG, Melichar B, Pienkowski T, Sirbu D, Messinger D, Zielinski C, Central European Cooperative Oncology Group (2013) Bevacizumab plus paclitaxel versus bevacizumab plus capecitabine as first-line treatment for HER2-negative metastatic breast cancer: interim efficacy results of the randomised, open-label, non-inferiority, phase 3 TURANDOT trial. Lancet Oncol 14:125–133
15. Albain KS, Nag SM, Calderillo-Ruiz G, Jordaan JP, Llombart AC, Pluzanska A, Rolski J, Melemed AS, Reyes-Vidal JM, Sekhon JS, Simms L, O’Shaughnessy J (2008) Gemcitabine plus paclitaxel versus paclitaxel monotherapy in patients with metastatic breast cancer and prior anthracycline treatment. J Clin Oncol 26:3950–3957
16. Kümler I, Christiansen OG, Nielsen DL (2014) A systematic review of bevacizumab efficacy in breast cancer. Cancer Treat Rev 40:960–973